
    
      Endpoints:

      Primary: To assess safety parameters including adverse and serious adverse events (incidence,
      causality, severity), local and systemic tolerance to the administered study treatment,
      changes in laboratory values and vital signs in patients with solid tumor; Secondary: to
      measure some tumor responses in using imaging technique, serological tumor markers, immune
      monitoring and metabolic monitoring.
    
  